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RESUMO 
Actualmente, a resistência a drogas é um dos grandes problemas na terapia de diferentes 
patologias e também na biotecnologia e agricultura.  
O objectivo do presente estudo foi elucidar a resistência a drogas em leveduras 
patogénicas ou alimentares, que mais frequentemente são encontradas. Assim, diferentes 
antifungicos clínicos e novos compostos recentemente sintetizados foram testados por 
um  método para avaliar a resistência e sua reversão que foi previamente desenvolvido.  
Foi testado um painel de diferentes drogas para reverter a resistência. Mostramos que 
alguns destes moduladores foram capazes de reverter eficazmente a resistência.  
Palavras-Chave: Resistência em leveduras; compostos antifúngicos; reversão de 
resistência. 
ABSTRACT 
Nowadays, drug resistance is one of the major problems in the therapy of different 
pathologies and also in agriculture and biotechnology. 
The aim of the present study is to elucidate drug resistance and its reversion in some of the 
more common pathogenic and foodborn yeasts. Thus, different clinical antifungal agents of 
more common use as well as new synthesized compounds were tested by a previously 
developed method to detect resistance and its reversion.  
A panel of different drugs was tested to lower the resistance to the antifungal agents. We 
have shown that some of these were able to lower resistance.  
Key-Words: Yeast resistance; antifungal agents; reversion of resistance patterns. 
 
1. INTRODUCTION 
An increasing number of resistant cells are emerging in different biological fields. Among them it is well 
established that Candida species displays increasing resistance to antifungal therapy by mechanisms not 
yet well established (White  et al., 1998). On the other hand, the opportunistic infections by “non 
pathogenic” yeast are also increasing, namely in AIDS, other immunodepressed patients, transplanted 
patients and those in critical conditions admitted to the intensive care units (Schwenke, 1992; Sajben  et 
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al., 1993; Krcmery, 1998; Lamb et al., 1997). Hence, nowadays any yeast species can be considered, in 
exceptional cases, as a potentially pathogenic one. 
Multidrug resistance (MDR) is exhibited by a wide variety of prokaryotic and eukaryotic cells and among 
drug resistance mechanisms has been identified as one of the more generalized (Prudêncio, 2000). This 
mechanism is associated with the active efflux of toxic compounds from the cells and is mediated by 
active efflux proteins (AEP) and is present in fluconazole and other azole resistant Candida species 
(Clark, et al.,1996; Carlson et al., 1996; Sanglard et al., 1995; Parkinson, et al., 1995; Marichal and 
Vanden Bossche, 1995; Walsh, 1997; Hernaez, 1998). 
In order to further elucidate the mechanism(s) underlying drug resistance in yeasts, the clinical antifungal 
agents fluconazole, 5-fluorocytosine and amphotericin B were selected in previous studies (Prudêncio et 
al., 2000) among those of more common use.  
For this purpose the studies were conducted in isolates of Candida spp. namely, Candida albicans, 
Candida tropicalis and Candida krusei. The yeast species Saccharomyces cerevisiae and Kluyveromyces 
marxianus were selected, since they were already reported as resistant to antimicrobial agents, being the 
resistance mechanism related to the induction of AEP (Prudêncio, 2000) and additionally Issatchenka 
Orientalis.  
In a second phase new drugs were tested. Primaquine is a drug widely used against malaria disease in the 
last forty years, due to its action against different forms of malaria parasites. However some problems are 
still raised: rapid metabolic inactivation to form carboxyprimaquine  and serious blood toxicity, with 
particular ability to induce oxidation of oxyhemoglobin to methemoglobin
 
(Constantino et al., 1999; 
Brueckner et al 2001). 
One possible way to reduce the primaquine toxicity is its transformation into an imidazolidin-4-one
 
(Gomes et al 2004;  Araújo et al 2005). Compounds of this kind are being synthesized to develop new 
approaches for the implementation of more effective treatments against malaria (Gomes et al 2004). 
Recently it has been observed that primaquine derivatives could also have antifungal activity
 
(Thomas et 
al, 2000). The compound used in the present work was the 5-isopropyl-3-[4-(6-methoxy-quinolin-8-
ylamino)-pentyl]-2,2-dimethyl-imidazolidin-4-one (ValPQacet) that was synthesized through acylation of 
the anti-malarial primaquine with L-valine and subsequent reaction of the resulting a-aminoamide with 
propanone (Gomes et al 2004). 
Finally in an attempt to revert the resistance phenotype of the yeast species to the antifungals tested, a 
panel of different compounds described as substrates or as inhibitors of MDR proteins in different types 
of cells (Kolaczkowski et al., 1998; Kolaczkowski  et al., 1996; Krishnamurthy et al., 1998; Paul et al., 
1996; Prasad et al., 1995; Holló., 1994 and Homoloya 1993; Krishan 1994) were tested. 
 
 
2. MATERIALS AND METHODS 
2.1 Microorganisms and growth conditions: 
The yeast species studied were: Saccharomyces cerevisiae IGC 4072, Candida tropicalis PYCC, 
Issatchenka Orientalis PYCC 3341 and Kluyveromyces marxianus IGC 2671 from the Portuguese Yeast 
Culture Collection (PYCC), Universidade Nova de Lisboa, Portugal. The two yeast species Candida 
albicans H33 and Candida Krusei H9 were selected from clinical isolates received in the laboratory of 
Serviço de Microbiologia da Faculdade de Medicina da Universidade do Porto. These yeasts were 
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previously identified to the species level by the API 20C system and the means of identification were 
supplemented when needed by conventional morphological and biochemical methods. Each isolate 
represented a unique isolate from a patient and was maintained on agar slants (Prudêncio et al, 1998) with 
2% (w/v) of glucose. Cells were grown in a mineral medium (MGV) with vitamins (van uden, 67) 
supplemented with 2% (w/v) of glucose and incubated on a mechanical shaker at 25ºC. 
2.2 Chemicals 
The clinical antifungals 5-fluorocytosine and amphotericin B and verapamil, cycloheximide, vinblastine, 
taxol, progesterone, corticosterone and sodium fluoride (NaF) were purchased from Sigma Chemical Co. 
-estradiol, from Merck (Darmstadt, Germany). The agriculture fungicides, 
benomyl and penconazol were purchased from Riedel-de Haën (Chinosol, Seelze). Fluconazol (Diflucan) 
was purchased from Pfizer (Laboratórios Pfizer, Lda. Seixal, Portugal) in an intravenous infusion solution 
of 2 mg/ml.  
 
2.3 Determination of the minimum inhibitory concentrations (MIC) and treatments with the antifungals 
The determination of the MIC for the antifungals were performed according to (Prudêncio et al 1999). 
For the treatments with the antifungals, the yeast cells were suspended in PBS with 2% (w/v) of glucose 
and incubated with fluconazole, 5-fluorocytosine and amphotericin B at room temperature for at least 180 
minutes. The concentrations used for the different antimicrobial agents were below the MIC determined 
for each yeast species and confirmed not to be cytotoxic by counting colony forming units. In the 
experiments with the modulators these were added in the presence of the antifungals for which the cell 
was resistant. The modulators were tested independently for cytotoxicity (data not shown), being used at 
subinhibitory concentrations, according to Table 4. The new compounds obtained by organic synthesis, 
were included in the medium and the cells were grown in the absence or in the presence of ValPQacet, 
PQ and NaCl. The specific growth constants (kc) determinations were determined according to 
(Prudêncio, 1995). 
2.4 Statistical analysis 
The data were compared by the Student´s t test. 
 
3. RESULTS AND DISCUSSION 
The minimum inhibitory concentrations (MIC) of ValPQacet, primaquine (PQ) and NaCl, were 
determined for the yeast species presented in Table 1. Since ValPQacet and PQ are bis-hydrochloride 
salts, the toxicity of NaCl at the same Cl
-
 concentration was also tested, as a control for the inhibitory 
effects of hydrochloride. The results obtained for the MIC determinations are shown in Table 1. For C. 
tropicalis it was not possible to determine the MIC value since the occurrence of a halo at 0.5 mg/L of 
ValPQacet was also observed for similar concentrations of PQ and NaCl. Further studies are needed to 
understand this result. In the case of C. albicans ValPQacet seems to induce the same effects than PQ. 
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Table 1 - Inhibitory effects induced by different concentrations of ValPQacet, primaquine bis-
hydrochloride (PQ) and sodium chloride (NaCl). The observation of haloes (growth inhibition) is 
indicated by (+) and non-observation by (-). The minimum inhibitory concentration (MIC) determined 
are indicated in bold. 
Yeast species ValPQacet PQ NaCl* Concentration
(mg/L)
S. cerevisiae
PYCC 4072
+ + - 5000
+ - - 500
+ - - 50
+ n.d n.d 5
- n.d n.d 0.5
- n.d n.d 0.05
I. orientalis
PYCC 3341
+ - - 5000
+ - - 500
+ - - 50
+ n.d n.d 5
+ n.d n.d 0.5
+ n.d n.d 0.05
+ n.d n.d 0.005
+ n.d n.d 0.0005
- n.d n.d 0.00005
C. albicans
PYCC 3436T
+ + - 5000
- - - 500
- - - 50
C. tropicalis
PYCC 3092 T
+ + + 5000
+ + + 500
+ + + 50
+ + + 5
+ + + 0.5?
- + + 0.05
- n.d n.d 0.005
- n.d n.d 0.0005
- n.d n.d 0.00005
 
n.d. non determined values; *NaCl concentration always doubled that of ValPQacet and PQ, since these are bis-
hydrochloride salts. 
 
The comparison of the MIC values obtained for ValPQacet and PQ, are summarized in Table 2. With the 
exception of C. albicans the potential antifungal application of ValPQacet seems interesting since the 
inhibitory effects observed were increased 10
5 
times for I. orientalis and 1000 times for S. cerevisiae 
when compared with the parent drug, PQ. These observations are reinforced when the MIC values of 
fluconazol (32 mg/L), 5-fluorocitosine (>200mg/L) and amphotericine B (8 mg/L) for S. cerevisiae are 
compared with those obtained for ValPQacet (Prudêncio et al., 2000). The values obtained for I. 
orientalis (Table 2) are much lower when compared with the other yeast species tested. 
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Table 2- Minimum inhibitory concentration (MIC) of ValPQacet and of primaquine hydrochloride 
salt (PQ) and the clinical antifungals*, determined for all the yeast species studied. 
Agentes 
Antimicrobianos 
(mg/L) 
C. krusei C. albicans S. cerevisiae K. marxianus I. orientalis 
Fluconazol >128* 10* 32* 0,5* -- 
5-fluorocitosine >200* >200* >200* <10* -- 
Amphotericine B 8* 5* 8* 8* -- 
ValPQacet -- 5000 5 -- 0,005 
PQ -- 5000 5000 -- >5000 
* Prudêncio, 2000. 
 
In order to further understand the inhibitory effect induced by ValPQacet, the  specific growth constants 
(kc) for S. cerevisiae were determined in the absence and in the presence of  2.5 mg/L and 5 m/L of 
ValPQacet. Additionally, kc values were compared with those obtained in the presence of 5 mg/L PQ and 
10 mg/L NaCl (Table 3). The values obtained further reinforce the idea that NaCl does not seem to inhibit 
growth in the concentration tested, whereas PQ seems to increase growth slightly at the concentration 
tested when compared with the control. The inhibitory effects on growth observed in the presence of 
ValPQacet at the MIC value (5 mg/L) seem to decrease kc by 33%, when compared with the control, 
whereas at half the concentration (2,5 mg/L) the kc observed is similar to that obtained for PQ, showing a 
dose/effect relation. 
 
Table 3- Specific growth constants (kc) determined for S. cerevisiae in the absence and in the presence of 
ValPQace, PQ and NaCl.  
Concentration
(mg/L)
kc (min 
-1) in the presence 
of ValPQacet
kc (min 
-1) in the 
presence of PQ
kc (min 
-1) in the 
presence of NaCl
0 3.40 10-3+ 0,34    3.40 10-3+ 0,34        3.40 10-3+ 0,34        
2,5 4.40 10-3+ 0,17    n.d n.d
5 2.62 10-3+ 0,16  4.13 10-3+ 0,0  3.56 10-3+ 0,29  
 
3.1 Reversion of resistance phenotype 
Different compounds were tested in an attempt to revert the resistance phenotype obtained previously 
(Prudêncio, 2000) in S. cerevisiae and C. albicans (Table 4). These compounds, as referred before, are 
described as inhibitors or as being transported by MDR proteins in different types of cells or are 
compounds already used in clinical, but for other purposes. Those of the first group so were tested for 
competitive or non competitive inhibition of the transporter and in any of this cases if a compound 
functions as modulator it would increase antifungal retention and hence toxicity, so the resistance would 
decrease. The second group of compounds was tested for its potential as antifungals in addition to their 
known clinical functions. 
For this purpose the cells were incubated in the presence of the different concentrations of the antifungal 
agents for witch they exhibit resistance and of a panel of different modulators. The concentrations used 
for the modulators were subinhibitory and previously confirmed as noncitotoxic by counting colony 
forming units (CFU). 
The results presented in Table 4, show the decrease of the MIC value for C. albicans and S. cerevisiae in 
the presence of several the modulators of those tested. These compounds presented the ability to revert 
the resistance presented to 5-fluorocytosine. For the yeast C. albicans, in our experimental conditions, 
fewer compounds showed an activity to revert the resistance phenotype than for the yeast S. cerevisiae. 
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Table 4 - Minimum inhibitory concentrations (MICs) of 5-fluorocitosine in the presence of 
modulators (sub-inhibitory concentrations) in the yeasts C. albicans and S. cerevisiae. 
 
 
 
S. cerevisiae 
 
5-fluorocitosina 
MIC > 200 mg/L 
*Anfotericina B (5 mg/L) =100 
*Benomil (50 mg/L) =100 
*penconazol (10 mg/L) =200 
*Vinblastina (5 M) =50 
*- estradiol (50 M) =50 
*Progesterona (5 M) =200 
*Corticosterona (5 M) =100 
 Acetilsalicilato de Lisina (0,1 mg/L) =100 
 Ibuprofeno (0,1 mg/L) =200 
 Paracetamol (0,1 mg/L) =100 
C. albicans 
 
5-fluorocitosina 
MIC > 200 mg/L 
Acetilsalicilato de Lisina (0,1 mg/L) =100 
Ibuprofeno (0,1 mg/L) >200 
Paracetamol (0,1 mg/L) =200 
*Penconazol (10 mg/L) <20 
*Prudêncio, 2000 
4. CONCLUSIONS 
The new primaquine imidazolidin-4-one prepared seem to be interesting as a potential antifungal agent 
against several yeasts other than C. albicans.  
The MIC value of new primaquine imidazolidin-4-one prepared for S. cerevisiae (5mg/L) indicates its 
potential application as an antifungal agent, which was further reinforced when compared with the MIC 
values previously determined (Prudêncio, 2000) for fluconazol (32 mg/L) and penconazol (20 mg/L), two 
of the most used antifungal agents for clinical and agriculture purposes, respectively. 
In S. cerevisiae a dose/effect relationship was observed, according to the results obtained for kc values. 
Several modulators tested, showed a function in the reversion of the resistance phenotype previously 
determined (Prudêncio, 2000). These results are promising and may be useful in clinical, biotechnology 
and agriculture.  
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